These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

984 related articles for article (PubMed ID: 23141174)

  • 1. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The changes in residual cancer burden after interval debulking surgery are effective in evaluating the response to adjuvant chemotherapy.
    Kong L; Li X; Xu Q; Wei L; Wang J; Cui H; Wang S; Zhao Y
    Chemotherapy; 2011; 57(3):209-16. PubMed ID: 21555882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
    Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
    Zhao D; Wu LY; Wang XB; Li XG
    Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
    Skírnisdóttir I; Lindborg K; Sorbe B
    Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
    Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
    J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.
    Parashkevova A; Sehouli J; Richter R; Dimitrova D; Braicu EI; Muallem MZ
    Anticancer Res; 2018 Aug; 38(8):4865-4870. PubMed ID: 30061261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
    Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
    Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.
    Bilici A; Salepci T; Dane F; Gumus M; Ustaalioglu BB; Seker M; Salman T; Turan C; Unal O; Yaylaci M
    Arch Gynecol Obstet; 2010 Oct; 282(4):417-25. PubMed ID: 20035339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
    Jansaka N; Suprasert P
    Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment CA 15-3 levels do not predict disease-free survival in patients with advanced epithelial ovarian cancer.
    Gemer O; Oustinov N; Gdalevich M; Dubnik S; Levy R; Yachnin A; Lavie O; Ben Baruch N; Ben Arie A
    Tumori; 2013; 99(2):257-60. PubMed ID: 23748823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Chen X
    Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
    Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
    J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
    Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
    da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
    Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.